Protein Degrader uses the natural mechanism of protein degradation in cells, that is, the ubiquitin-protease system, to induce targeted protein degradation. Compared with traditional small molecular inhibitors used in cancer therapy, ProteinRead More…
Recently, the Li Zigang and Yin Feng research group of Shenzhen Graduate School of Peking University published a research paper entitled “Targeted biomolecule regulation platform: a Split-and-Mix Protein Degrader approach” in JournalRead More…
Enzyme-Catalyzed Responsive Pro-Protein Degrader The researchers concentrated on the distinction between the tumor microenvironment and the normal cell environment and incorporated the endogenous enzyme response chemistry of tumor cell characteristics into theRead More…
Chemical protein degradation methods like protein degradation targeted chimera (Protein Degrader) allow for the simultaneous targeting of E3 ligase and disease-related proteins, with the latter then being degraded by the body’s ownRead More…
Compared with traditional drugs, Protein Degrader molecules have many advantages. Protein Degrader molecule is covalently linked by the target protein ligand and E3 ubiquitin ligase ligand. After binding to the target protein,Read More…
Protein Degrader technology, by linking E3 ubiquitin ligase to the target protein, leads to the ubiquitin modification of the target protein which is broken down into peptides and amino acids by proteasome.Read More…
New lung cancer diagnoses and deaths have decreased as a result of reduced smoking and advances in early screening and treatment. However, lung cancer remains the leading cause of cancer deaths, accountingRead More…
Protein degradation targeted chimera (Protein Degrader) can efficiently degrade disease-causing proteins to treat varieties of diseases and has been widely investigated by global researchers. Despite of its promising prospects, the pharmacokinetic behaviorRead More…
Glioma is a primary intracranial malignant tumor originating from glial cells or progenitor cells, accounting for 25.5% of central nervous system tumors. Clinically, the treatment of glioma mainly depends on surgical resection,Read More…
Acute lymphoblastic leukemia (ALL) is a common disease. B-ALL and T-ALL account for 85% and 15% of the two lymphatic lineages of ALL, respectively, but patients with T-ALL have poor life qualityRead More…